With a market cap of $11.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, ...

Germany’s Merck KGaA will buy Bio-Techne Corp. in a deal worth $11.3 billion, one of the largest acquisitions in Minnesota history. The sale follows investor pressure on Minneapolis-based Bio-Techne, ...

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...

German drugmaker Merck ​KGaA said on Thursday it will acquire U.S. biotech firm Bio-Techne for $11.3 billion, its largest deal in over a decade.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist.

An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...

View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.